An update on anti-TNF agents in ulcerative colitis

Gastroenterol Clin North Am. 2014 Sep;43(3):479-94. doi: 10.1016/j.gtc.2014.05.006.

Abstract

Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials.

Keywords: Adalimumab; Anti-TNF; Golimumab; Infliximab; UC; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Drug Monitoring
  • Drug Therapy, Combination
  • Humans
  • Infliximab
  • Intestinal Mucosa / drug effects
  • Maintenance Chemotherapy
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Wound Healing / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Infliximab
  • Adalimumab